JP2024521920A5 - - Google Patents
Info
- Publication number
- JP2024521920A5 JP2024521920A5 JP2023574589A JP2023574589A JP2024521920A5 JP 2024521920 A5 JP2024521920 A5 JP 2024521920A5 JP 2023574589 A JP2023574589 A JP 2023574589A JP 2023574589 A JP2023574589 A JP 2023574589A JP 2024521920 A5 JP2024521920 A5 JP 2024521920A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- heterocyclyl
- cycloalkyl
- heteroaryl
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163196008P | 2021-06-02 | 2021-06-02 | |
| US63/196,008 | 2021-06-02 | ||
| US202263362438P | 2022-04-04 | 2022-04-04 | |
| US63/362,438 | 2022-04-04 | ||
| US202263364360P | 2022-05-09 | 2022-05-09 | |
| US63/364,360 | 2022-05-09 | ||
| PCT/US2022/072693 WO2022256806A1 (en) | 2021-06-02 | 2022-06-01 | Combination therapy comprising a mat2a inhibitor and a type ii prmt inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024521920A JP2024521920A (ja) | 2024-06-04 |
| JP2024521920A5 true JP2024521920A5 (enExample) | 2025-06-11 |
Family
ID=84323602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023574589A Pending JP2024521920A (ja) | 2021-06-02 | 2022-06-01 | Ｍａｔ２ａ阻害剤及びｉｉ型ｐｒｍｔ阻害剤を含む併用療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20240108626A1 (enExample) |
| EP (1) | EP4347569A4 (enExample) |
| JP (1) | JP2024521920A (enExample) |
| KR (1) | KR20240019172A (enExample) |
| AU (1) | AU2022287057A1 (enExample) |
| BR (1) | BR112023025360A2 (enExample) |
| CA (1) | CA3220160A1 (enExample) |
| CL (1) | CL2023003603A1 (enExample) |
| IL (1) | IL308853A (enExample) |
| MX (1) | MX2023014405A (enExample) |
| WO (1) | WO2022256806A1 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11077101B1 (en) | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
| MX2021006841A (es) | 2018-12-10 | 2021-07-02 | Ideaya Biosciences Inc | Derivados de 2-oxoquinazolina como inhibidores de metionina adenosiltransferasa 2?. |
| WO2021086879A1 (en) | 2019-10-28 | 2021-05-06 | Tango Therapeutics, Inc. | Compounds and methods of use |
| EP4188920A1 (en) | 2020-07-31 | 2023-06-07 | Tango Therapeutics, Inc. | Piperidin-1-yl-n-pyrydine-3-yl-2-oxoacetamide derivatives useful for the treatment of mtap-deficient and/or mta-accumulating cancers |
| KR20240019172A (ko) * | 2021-06-02 | 2024-02-14 | 아이디어야 바이오사이언시스 인코포레이티드 | Mat2a 억제제 및 유형 ii prmt 억제제를 포함하는 병용 요법 |
| EP4458812A1 (en) * | 2021-12-27 | 2024-11-06 | Medshine Discovery Inc. | Pyrazole-1(2h)-phthalazinone compound and application thereof |
| US20250171432A1 (en) * | 2022-01-26 | 2025-05-29 | Tango Therapeutics, Inc. | Compounds and methods of use |
| WO2023202626A1 (zh) * | 2022-04-22 | 2023-10-26 | 北京望实智慧科技有限公司 | 稠和哒嗪酮化合物作为prmt5抑制剂 |
| WO2023246873A1 (zh) * | 2022-06-23 | 2023-12-28 | 南京明德新药研发有限公司 | 氨基取代的杂芳基衍生物及其应用 |
| EP4549442A1 (en) * | 2022-07-01 | 2025-05-07 | Cytosinlab Therapeutics Co., Ltd. | Prmt5 inhibitors and use thereof |
| WO2024027703A1 (zh) * | 2022-08-02 | 2024-02-08 | 上海艾力斯医药科技股份有限公司 | 一种prmt5抑制剂、其制备方法及应用 |
| JP2026508792A (ja) * | 2022-10-25 | 2026-03-13 | タンゴ セラピューティクス， インコーポレイテッド | 結晶形態、医薬組成物、及びその使用方法 |
| CN120265615A (zh) * | 2022-11-29 | 2025-07-04 | 正大天晴药业集团股份有限公司 | 含有二氢酞嗪的化合物 |
| WO2024118943A2 (en) * | 2022-11-30 | 2024-06-06 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a prmt5 inhibitor |
| TW202440126A (zh) * | 2022-11-30 | 2024-10-16 | 美商安進公司 | 利用ｍｔａ協作的ｐｒｍｔ５抑制劑和ｍａｔ２ａ抑制劑之癌症治療 |
| EP4644389A1 (en) * | 2022-12-30 | 2025-11-05 | Suzhou Puhe Biopharma Co., Ltd. | Prmt5-mta inhibitor |
| EP4653435A1 (en) * | 2023-01-17 | 2025-11-26 | Suzhou Puhe Biopharma Co., Ltd. | Prmt5-mta inhibitor |
| EP4694892A1 (en) * | 2023-04-13 | 2026-02-18 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a topoisomerase inhibitor, a splicing inhibitor sulfonamide, or a kif18 inhibitor |
| CN121175299A (zh) * | 2023-04-28 | 2025-12-19 | 智擎生技制药股份有限公司 | Mta协同性prmt5抑制剂 |
| CN121712509A (zh) | 2023-05-04 | 2026-03-20 | 锐新医药公司 | 用于ras相关疾病或病症的组合疗法 |
| CN116283800B (zh) * | 2023-05-16 | 2023-07-18 | 英矽智能科技(上海)有限公司 | 氧代喹唑啉类化合物及其应用 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| KR20260049253A (ko) * | 2023-08-08 | 2026-04-13 | 미라티 테라퓨틱스, 인크. | 악성 말초 신경초 종양을 치료하는 방법 및 조성물 |
| IL327063A (en) * | 2023-09-15 | 2026-05-01 | Ideaya Biosciences Inc | Methods for treating MAT2A-related diseases |
| CN121866246A (zh) * | 2023-09-20 | 2026-04-14 | 西藏海思科制药有限公司 | 一种含氰基的杂环化合物及其用途 |
| IL327306A (en) | 2023-10-12 | 2026-05-01 | Revolution Medicines Inc | Macrocyclic RAS inhibitors |
| CN121889382A (zh) * | 2023-11-08 | 2026-04-17 | 北京泰德制药股份有限公司 | Prmt5抑制剂及其制备方法 |
| TW202532070A (zh) * | 2023-12-01 | 2025-08-16 | 大陸商上海翰森生物醫藥科技有限公司 | 四並環類衍生物抑制劑、其製備方法和應用 |
| WO2025157286A1 (zh) * | 2024-01-26 | 2025-07-31 | 上海湃隆生物科技有限公司 | 包含prmt5抑制剂和mat2a抑制剂的药物组合物 |
| WO2025166308A1 (en) * | 2024-01-31 | 2025-08-07 | Tango Therapeutics, Inc. | Crystalline forms, pharmaceutical compositions and methods of use thereof |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217297A1 (en) * | 2024-04-09 | 2025-10-16 | Tango Therapeutics, Inc. | Prmt5 inhibitors for use in methods of treating mta-accumulating cancer |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025250569A1 (en) * | 2024-05-29 | 2025-12-04 | Amgen Inc. | Cancer treatments using mta-cooperative prmt5 inhibitors and mat2a inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018006781A (es) * | 2015-12-03 | 2018-11-09 | Agios Pharmaceuticals Inc | Inhibidores de mat2a para el tratamiento del cancer que no expresen mtap. |
| MX2021006841A (es) * | 2018-12-10 | 2021-07-02 | Ideaya Biosciences Inc | Derivados de 2-oxoquinazolina como inhibidores de metionina adenosiltransferasa 2?. |
| US11492351B2 (en) * | 2019-09-12 | 2022-11-08 | Mirati Therapeutics, Inc. | MTA-cooperative PRMT5 inhibitors |
| CR20220175A (es) * | 2019-10-22 | 2022-06-21 | Lupin Ltd | Combinación farmacéutica de inhibidores de PRMT5 |
| WO2021086879A1 (en) * | 2019-10-28 | 2021-05-06 | Tango Therapeutics, Inc. | Compounds and methods of use |
| KR20240019172A (ko) * | 2021-06-02 | 2024-02-14 | 아이디어야 바이오사이언시스 인코포레이티드 | Mat2a 억제제 및 유형 ii prmt 억제제를 포함하는 병용 요법 |
-
2022
- 2022-06-01 KR KR1020237045309A patent/KR20240019172A/ko active Pending
- 2022-06-01 JP JP2023574589A patent/JP2024521920A/ja active Pending
- 2022-06-01 WO PCT/US2022/072693 patent/WO2022256806A1/en not_active Ceased
- 2022-06-01 IL IL308853A patent/IL308853A/en unknown
- 2022-06-01 MX MX2023014405A patent/MX2023014405A/es unknown
- 2022-06-01 CA CA3220160A patent/CA3220160A1/en active Pending
- 2022-06-01 AU AU2022287057A patent/AU2022287057A1/en active Pending
- 2022-06-01 EP EP22817027.0A patent/EP4347569A4/en active Pending
- 2022-06-01 BR BR112023025360A patent/BR112023025360A2/pt unknown
-
2023
- 2023-11-03 US US18/501,729 patent/US20240108626A1/en active Pending
- 2023-12-01 CL CL2023003603A patent/CL2023003603A1/es unknown
-
2024
- 2024-01-05 US US18/405,638 patent/US12115163B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022512156A5 (enExample) | ||
| RU2455288C2 (ru) | Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ | |
| ES2237650T3 (es) | Proceso para la preparacion de compuestos de imidazol trisustituidos con multiples propiedades terapeuticas. | |
| RU96103386A (ru) | Три-замещенные имидазолы, обладающие многочисленными терапевтическими свойствами, способ получения, фармацевтическая композиция, способ лечения | |
| JP2013507449A5 (enExample) | ||
| JP2014511869A5 (enExample) | ||
| JP2018527336A5 (enExample) | ||
| JP2007519692A5 (enExample) | ||
| JP2008517945A5 (enExample) | ||
| RU2007130532A (ru) | Дизамещенные мочевины в качестве ингибиторов киназы | |
| JP2018511587A5 (enExample) | ||
| JP2007504160A5 (enExample) | ||
| JP2008510828A5 (enExample) | ||
| SK287277B6 (sk) | Deriváty imidazol-5-yl-2-anilinopyrimidínov, spôsob ich prípravy a farmaceutická kompozícia, ktorá ich obsahuje | |
| JP2013517283A5 (enExample) | ||
| JP2010540452A5 (enExample) | ||
| JP2007523905A5 (enExample) | ||
| JP2009526072A5 (enExample) | ||
| RU2007127834A (ru) | Производные 1, 6-замещенного (3r, 6r)-3-(2, 3-дигидро-1н-инден-2-ил)-2, 5-пиперазиндиона в качестве антагонистов рецептора окситоцина для лечения преждевременных родов, дисменореи и эндометриоза | |
| JP2008513500A5 (enExample) | ||
| JP2012510989A5 (enExample) | ||
| JP2010529991A5 (enExample) | ||
| JP2003535887A5 (enExample) | ||
| JP2007505922A5 (enExample) | ||
| CA2643055A1 (en) | Tetralines antagonists of the h-3 receptor |